BETTING ON THE TRIFECTA?
My idea of a trifecta win right now would involve some significant milestones coming in from a company I am invested in that rolls out into 3 or more major news developments in a small amount of time. The perfecta trifecta !!!
Lets face it the past 60 days have not been very exciting to watch the stock market on both sides of the border. I don't usually indulge in the southern flavor but do keep a constant watch for an opportunity in any sector.
The Canadian markets have been bleeding across the board and today was no different. Metals dropping, the TSX dropping and all the while you have to think of all the deals that are available to a guy sitting on cash. Unfortunately I am not that guy since I blew my wad on a few stocks that I couldn't resist, even though I knew the prices would get better for buyers as tax selling kicks into high gear. How low can this go? That's what I ask myself when I track good companies hit by an uncertain market. There is no easy answer since you can't peer into the mind of every share holder that may be under the gun to put bread on the table around Christmas time.
Each year I do wait longer to put in all of my cash but the smart guys are just now starting to make there move since some stocks have really bottomed out. There are so many that I wouldn't know where to start when it came to calling out their names and symbols. Lets just say its happening everywhere and it's time for you decide if you want to step up your game or crawl back into your 9-5 another year while others take the leap to financial freedom. It's not easy but I did it, I made the move that changed my life by doing some good due diligence on a handful of companies that all ran with the wind in the 90 days following the tax loss selling season.
I am sure a lot of you witnessed these runs and wondered what it would have been like to load up on those runners at a time when everyone seemed to be selling. Well it felt great!! But at the same time it was very scary. You can second guess yourself a million times before jumping in and then holding your breath to see if you made the right move. It's not for everyone that's for sure. But when you nail it and you see the fruits of your labor kick in the funny thing is you really have just fought part of the battle. The real battle internally starts when you feel you can make up for 30-40 years of bad decisions with one stock on the TSX-V. That's the real problem in front of you now. You have a huge win and you can't pull the trigger. All the what if's start to creep into your head. What if this doubles again or triples?
Take a deep breath and think of it this way. Who could have known a Tsunami would hit Japan and wipe out gains on Uranium stocks in a few hours? Who could have predicted that China would flood the market with an element that your company just found in Spain? So many things can happen in the blink of an eye and profit is only profit if you take it home with you. Remember that there are so many more stocks to invest in and so many more wins ahead that you can play since you took profit. You can't say this if you stood by and didn't sell only to watch all of your profit and part of your original investment evaporate in front of you.
Now that I have you thinking about value, profit and what you are going to do next year you should take the time to make a plan. Seriously I bet so many investors just wing it day to day on the TSX-V. I don't want to pick on that exchange but it seems to be where the best short term gains can be realized while still trading on a very regulated exchange. I'm all about profit and when it turns out my game plan has changed because some time lines are now longer than the company first predicted I usually take it on the chin and wait it out. It's still the company I found, researched and invested in. Nothing else has changed.
In December I like to present a list of stocks I will be watching in the following year. In 2013 you can expect to see Gold, Medical, Alternative Fuel and a few surprises that have been off most traders radar. I'm going to give you a look at one of the companies because I think a lot of investors have only done a cursory investigation of what this company has to offer.
Miraculins has three key events on my radar that could make it my Trifecta in the coming weeks. First off I am waiting to see a breakdown of the deal with London Drugs for PreVu and what the future will hold as far as a long term relationship.
The PREVU* Skin Cholesterol Test non-invasively, painlessly and rapidly
measures skin cholesterol. As a new risk factor
for heart disease, skin cholesterol provides valuable
additional information to traditional CAD risk assessment. Skin
contains
over 11% of the body’s cholesterol and ages in parallel
with vascular connective tissue. As arterial walls accumulate
cholesterol,
so do the skin tissues. A high skin cholesterol level is a
reliable predictor of higher cholesterol accumulation in the arteries
and,
accordingly, can be used in combination with other risk
factors to assess risk of coronary artery disease.
The product has
previously received FDA clearance for sale in the United
States and additional regulatory approvals in Canada and Europe.
PREVU* has been successfully test marketed on a limited
basis in North America.
Next I am waiting to hear on an Eastern Canada partner/launch that seems to have been set up with the launch of a new French web site. Not too sneaky but very effective at grabbing my attention.
Lastly I want to shed some light again on the relationship with Alere. Preeclampsia is not something we run into on a daily basis. A lot of investors don't understand it or the technology behind it. I am sure Alere has done their home work and soon will be in a position to fully license or pass on this. A move to license could open a very big door as far as revenues go and this would complete my short term Trifecta in the markets.
Preeclampsia program
Preeclampsia (PE) is a pregnancy specific disease that is
characterized by hypertension and proteinuria. It is generally
accepted that the exact causes of PE are unkown. If the pregnancy is
left to continue to full term with PE present, the disease will
progress to Eclampsia and result in seizure, coma and mortality.
Screening for preeclampsia
To date there are no reliable diagnostics or biomarkers that
can accurately predict the onset of PE available for patients. PE is
currently diagnosed by its symptoms which are non-specific to PE.
Miraculins' preeclampsia diagnostic test
In October 2008, Miraculins announced the execution of a
license agreement with Mount Sinai hospital to acquire the rights to
commercialize a portfolio of biomarkers for use in developing
diagnostic assays for the early detection of preeclampsia. In January
2010 the program was partenred with Inverness Medical innovations (NYSE:
IMA), one of the world's largest diagnostics companies.
Diagnosing PE in the early stages of a pregnancy can:
Help women avoid an unexpected traumatic event when they go into labour
Aid in the decision to manage PE patients with bed rest, vitamins and extra care during pregnancy
Could help researchers develop PE therapeutics
Preeclampsia facts
PE is the leading cause of maternal and prenatal deaths worldwide, affecting 7-10 percent of all pregnancies
In the US alone, PE is responsible for 18
percent of all maternal deaths, 80,000 premature births and numerous
neonatal complications
It is estimated that preeclampsia costs the global health care system US $3 billion per year
The Miraculins advantage
Miraculins focuses on in-licensing/acquiring and developing
both cancer and non-cancer diagnostic opportunities that have completed
early stage research and address unmet clinical needs.
Miraculins’ internal research program has lead to the discovery
and identification of prostate cancer biomarkers, the lead marker of
which is called Prostate Secretory Protein or PSP94. Miraculins also
acquired several biomarkers in the areas of Gastric, Colorectal, and
Pancreatic Cancer and are in the process of moving those programs
further through the pipeline.
With the experience gained from developing its first assay, and
the addition of a strong scientific team, Miraculins has developed a
process and criteria for evaluating technologies as potential licensing
targets.
Once Miraculins has determined that a specific technology meets
its criteria the Company adds value to the early stage research by
developing a clinical grade assay, confirming the diagnostic potential
of the technology and moving the test through to regulatory approval
and commercial sales.
Miraculins therefore bridges the gap between early stage
research, completed at the university/institution level, and clinical
grade commercial assays.
Under its new business model, Miraculins has acquired a panel
of Preeclampsia biomarkers from Mount Sinai Hospital and partnered the
program with Inverness Medical Innovations (NYSE:IMA), one of the
world’s largest diagnostic companies.
http://www.miraculins.com/the_miraculins_advantage.aspx
Disclosure: I am invested and long on MOM.V shares and may add to my position or sell at some point in the future. I was not compensated for writing this article and this is merely my opinion on the company going forward.
*PLEASE READ THE CONDITIONS OF USE FOR THIS BLOG!
CONTENT POSTED ON THIS BLOG DOES NOT CONSTITUTE A BUY OR SELL
RECOMMENDATION. MANY OF THE COMPANIES PROFILED HERE I AM NOT INVESTED IN
AND DO NOT INTEND TO INVEST IN. THESE ARE MERELY MY THOUGHTS ON MARKET
CONDITIONS AND STOCK VALUATIONS. INVESTING IN THE STOCK MARKET CAN BE
VERY RISKY AND YOU SHOULD ALWAYS CONSULT AN INVESTMENT PROFESSIONAL
BEFORE MAKING ANY DECISIONS. ULTIMATELY YOU ARE RESPONSIBLE FOR
CONDUCTING YOUR OWN DUE DILIGENCE AND PROTECTING YOUR MONEY.
PLEASE NOTE:
thetradersdigest.blogspot.com and its employees are not a Registered
Investment Advisor, Broker Dealer or a member of any association for
other research providers in any jurisdiction whatsoever.
